Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life

Seminars in Oncology

Volumn 33, Issue SUPPL. 12, 2006, Pages 8-17

  Alberts, David S ^a   Delforge, Ardie ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GRANISETRON; LORATADINE; LORAZEPAM; MAGNESIUM; MANNITOL; PACLITAXEL; PALONOSETRON; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ANXIETY; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CATHETER; CATHETER COMPLICATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEARING LOSS; HUMAN; LEUKOPENIA; METABOLIC DISORDER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SPLEEN RUPTURE; SURVIVAL RATE; TINNITUS; VOMITING;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG TOXICITY; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 33846107539     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.11.003     Document Type: Article

References (51)

1. NCI Clinical Announcement on Intraperitoneal Therapy for Ovarian Cancer. Available at: http://www.cancer.gov/clinicaltrials/developments/IPchemo-digest (accessed January 5, 2006)
2. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
3. Armstrong D.K., Bundy B., Wenzel L., et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: A Gynecologic Oncology Group Study. N Engl J Med 354 (2006) 34-43
4. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
5. Alberts D.S., Markman M., Armstrong D., et al. Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come!. J Clin Oncol 20 (2002) 3944-3946
6. Fujiwara K., Markman M., Morgan M., et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 97 (2005) 10-15
7. Walker J.L., Armstrong D.K., Huang H.Q., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100 (2006) 27-32
8. Wenzel L., Huang H., Armstrong D., et al. Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. Proc Am Soc Clin Oncol 23 (2004) 454 (abstr 5026)
9. Alberts D.S. A unifying vision of cancer therapy for the 21st century. J Clin Oncol 17 (1999) 13-21
10. Ozols R.F., Locker G.Y., Doroshow J.H., et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39 (1979) 3209-3214
11. Markman M., and Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 24 (2006) 988-993
12. Makhija S., Leitao M., Sabbatini P., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81 (2001) 77-81
13. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
14. NCCN Antiemesis Guidelines version 2.2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (accessed September 11, 2006)
15. Casper E.S., Kelsen D.P., Alcock N.W., et al. IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67 (1983) 235-238
16. Howell S.B., Pfeifle C.E., Wung W.E., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97 (1982) 845-851
17. Lopez J.A., Krikorian J.G., Reich S.D., et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20 (1985) 1-9
18. Francis P., Rowinsky E., Schneider J., et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group Pilot Study. J Clin Oncol 13 (1995) 2961-2967
19. Markman M., Reichman B., Hakes T., et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10 (1992) 1479-1484
20. Schneider J.G. Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 21 (1994) 195-212
21. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14 (1996) 2101-2112
22. Hilpert F., Stahle A., Tome O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13 (2005) 797-805
23. Kanat O., Evrensel T., Baran I., et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study. Med Oncol 20 (2003) 237-245
24. Lorusso D., Ferrandina G., Greggi S., et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 (2003) 1086-1093
25. De Vos F.Y., Bos A.M., Schaapveld M., et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 97 (2005) 60-67
26. Leong S.S., Tan E.H., Fong K.W., et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21 (2003) 1767-1774
27. Ethyol package insert. Gaithersburg, MD, MedImmune Oncology. Available at: http://www.medimmune.com/pdf/products/ethyol_pi.pdf (accessed September 13, 2006)
28. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 (2002) 2895-2903
29. Blumberg A.L., Nelson D.F., Gramkowski M., et al. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys 8 (1982) 561-563
30. Kligerman M.M., Glover D.J., Turrisi A., et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 10 (1984) 1773-1776
31. Shaw L.M., Turrisi A.T., Glover D.J., et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12 (1986) 1501-1504
32. Boccia R. Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin Oncol 29 suppl 19 (2002) 9-13
33. Boccia R.V., Alster M., and Houskamp E. Amifostine (Ethyol) given by rapid IV push is safe and tolerable. Proc Am Soc Clin Oncol 20 (2001) 300b (abstr 2953)
34. Kemp G.M., Kemp C.B., Mallee L.M., et al. Improved patient tolerability with short infusion amifostine (Ethyol). Proc Am Soc Clin Oncol 21 (2002) 267b (abstr 2888)
35. Koukourakis M.I. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs 13 (2002) 181-209
36. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 (1999) 3333-3355
37. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 (1991) 164-170
38. Heil G., Hoelzer D., Sanz M.A., et al., The International Acute Myeloid Leukemia Study Group. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90 (1997) 4710-4718
39. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29a (1993) 319-324
40. Biganzoli L., Untch M., Skacel T., et al. Neulasta (pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31 suppl 8 (2004) 27-34
41. Neuopogen (filgrastim) prescribing information. Thousand Oaks, CA, Amgen Inc. Available at: http://www.amgen.com/pdfs/misc/neupogen_pi.pdf (accessed September 14, 2006)
42. Morstyn G., Dexter T., and Foote M. Filgrastim (r-metHuG-CSF) in Clinical Practice. Ed 2. (1998), Marcel Dekker, New York, NY
43. Valerius T., Elsasser D., Repp R., et al. HLA Class-II antibodies recruit G-CSF activated neutrophils for treatment of B-cell malignancies. Leuk Lymphoma 26 (1997) 261-269
44. Johnston E., Crawford J., Blackwell S., et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18 (2000) 2522-2528
45. Holmes F.A., Jones S.E., O'Shaughnessy J., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 13 (2002) 903-909
46. McKenna P., Korach E., and Andersen P. Filgrastim-SD, a sustained duration form of filgrastim (rhuG-CSF) has similar effects on neutrophil function compared to filgrastim. Blood 92 suppl 1 (1998) 379a (abstr 1562)
47. Neulasta Product Information. Thousand Oaks, CA, Amgen Inc. Available at: http://www.neulasta.com/patient/pi.jsp#injection_site_selection_and_preparation (accessed October 20, 2006)
48. Gynecologic Oncology Group IP Chemotherapy Educational Materials. Available at: http://www.gog.org/ipchemoed/ipchemoed.html (accessed August 28, 2006)
49. American Society of Clinical Oncology. Available at: http://www.asco.org (accessed August 28, 2006)
50. Oncology Nursing Society. Available at: http://www.ons.org (accessed August 28, 2006)
51. Thompson S.D., and Horne A.L. Intraperitoneal Chemotherapy for Ovarian Cancer: A Nursing Management Perspective (2006). http://www.ovariancancercenter.org Available at: http://www.ovariancancercenter.org (accessed August 28)